Insmed CEDAR Study Misses Endpoints in HS Trial
BRIDGEWATER, N.J., April 7, 2026 Insmed Incorporated has announced that its Phase 2b CEDAR clinical trial evaluating brensocatib in...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
BRIDGEWATER, N.J., April 7, 2026 Insmed Incorporated has announced that its Phase 2b CEDAR clinical trial evaluating brensocatib in...
TAMPA, Fla., March 30, 2026 Concept Medical Inc. (CMI) announced the primary results of the SirPAD randomized controlled trial,...
Cambridge, Massachusetts, March 16, 2026 NeuroSense Therapeutics Ltd. announced the publication of results from its PARADIGM Phase 2b clinical...
NEW YORK, Oct. 14, 2025 – Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 HER2CLIMB-05...
Horsham, Pa., Sept. 29, 2025 – The U.S. Food and Drug Administration (FDA) has granted approval for TREMFYA® (guselkumab)...
INDIANAPOLIS, Sept. 17, 2025 – Eli Lilly and Company (NYSE: LLY) announced today that its investigational oral GLP-1 receptor...
NEW YORK & MAINZ, Germany – September 8, 2025 – Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX)...
Sanofi has secured U.S. FDA approval for Wayrilz (rilzabrutinib), marking the first Bruton’s tyrosine kinase (BTK) inhibitor approved for...
